Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 3161 | 1.62 |
09:34 ET | 3485 | 1.62 |
09:38 ET | 850 | 1.6298 |
09:41 ET | 900 | 1.635 |
09:43 ET | 5100 | 1.6467 |
09:45 ET | 3438 | 1.65 |
09:48 ET | 100 | 1.65 |
09:56 ET | 700 | 1.645 |
10:01 ET | 100 | 1.645 |
10:03 ET | 200 | 1.645 |
10:08 ET | 100 | 1.64 |
10:14 ET | 100 | 1.645 |
10:15 ET | 100 | 1.64 |
10:26 ET | 21628 | 1.65 |
10:28 ET | 200 | 1.645 |
10:30 ET | 100 | 1.645 |
10:33 ET | 3300 | 1.645 |
10:35 ET | 900 | 1.645 |
10:37 ET | 400 | 1.648 |
10:39 ET | 700 | 1.645 |
10:42 ET | 400 | 1.64 |
10:44 ET | 500 | 1.645 |
10:48 ET | 100 | 1.645 |
10:51 ET | 100 | 1.65 |
10:53 ET | 200 | 1.65 |
10:55 ET | 100 | 1.645 |
10:57 ET | 100 | 1.645 |
11:02 ET | 500 | 1.645 |
11:04 ET | 100 | 1.645 |
11:06 ET | 100 | 1.645 |
11:08 ET | 1200 | 1.645 |
11:11 ET | 400 | 1.64 |
11:13 ET | 100 | 1.64 |
11:15 ET | 100 | 1.65 |
11:18 ET | 14653 | 1.63 |
11:20 ET | 1400 | 1.63 |
11:22 ET | 1100 | 1.6234 |
11:24 ET | 100 | 1.62 |
11:26 ET | 700 | 1.62 |
11:27 ET | 100 | 1.625 |
11:29 ET | 200 | 1.62 |
11:31 ET | 3100 | 1.62 |
11:36 ET | 200 | 1.62 |
11:40 ET | 16047 | 1.61 |
11:42 ET | 700 | 1.61 |
11:44 ET | 18600 | 1.615 |
11:45 ET | 8574 | 1.61 |
11:47 ET | 2700 | 1.615 |
11:49 ET | 100 | 1.61 |
11:51 ET | 6310 | 1.615 |
11:54 ET | 100 | 1.62 |
11:56 ET | 300 | 1.62 |
11:58 ET | 2100 | 1.615 |
12:00 ET | 200 | 1.62 |
12:02 ET | 3154 | 1.615 |
12:03 ET | 200 | 1.615 |
12:05 ET | 300 | 1.615 |
12:07 ET | 100 | 1.615 |
12:09 ET | 200 | 1.615 |
12:12 ET | 200 | 1.615 |
12:16 ET | 100 | 1.61 |
12:21 ET | 300 | 1.61 |
12:23 ET | 100 | 1.61 |
12:25 ET | 397 | 1.615 |
12:32 ET | 400 | 1.61 |
12:36 ET | 200 | 1.615 |
12:39 ET | 100 | 1.61 |
12:41 ET | 100 | 1.61 |
12:50 ET | 300 | 1.61 |
12:57 ET | 100 | 1.61 |
12:59 ET | 900 | 1.61 |
01:01 ET | 200 | 1.61 |
01:03 ET | 100 | 1.61 |
01:06 ET | 100 | 1.62 |
01:10 ET | 200 | 1.61 |
01:12 ET | 1600 | 1.61 |
01:15 ET | 100 | 1.61 |
01:17 ET | 100 | 1.61 |
01:21 ET | 100 | 1.61 |
01:26 ET | 100 | 1.61 |
01:30 ET | 100 | 1.61 |
01:32 ET | 500 | 1.61 |
01:33 ET | 1200 | 1.61 |
01:37 ET | 567 | 1.6192 |
01:39 ET | 100 | 1.61 |
01:44 ET | 700 | 1.61 |
01:48 ET | 264 | 1.61 |
01:53 ET | 600 | 1.61 |
01:57 ET | 1000 | 1.6192 |
02:02 ET | 100 | 1.61 |
02:04 ET | 100 | 1.61 |
02:06 ET | 100 | 1.61 |
02:08 ET | 500 | 1.61 |
02:13 ET | 100 | 1.61 |
02:15 ET | 700 | 1.61 |
02:18 ET | 1134 | 1.605 |
02:22 ET | 200 | 1.6 |
02:24 ET | 400 | 1.6 |
02:26 ET | 2183 | 1.6 |
02:27 ET | 100 | 1.6 |
02:29 ET | 100 | 1.6 |
02:31 ET | 1100 | 1.61 |
02:33 ET | 200 | 1.6 |
02:40 ET | 1639 | 1.606 |
02:45 ET | 500 | 1.6 |
02:51 ET | 400 | 1.6 |
02:54 ET | 100 | 1.6 |
02:56 ET | 100 | 1.6 |
03:00 ET | 500 | 1.605 |
03:02 ET | 100 | 1.6 |
03:03 ET | 100 | 1.6 |
03:05 ET | 200 | 1.6 |
03:12 ET | 100 | 1.6 |
03:14 ET | 100 | 1.6 |
03:16 ET | 200 | 1.6 |
03:18 ET | 300 | 1.6 |
03:23 ET | 400 | 1.6 |
03:25 ET | 100 | 1.6 |
03:27 ET | 5925 | 1.6 |
03:32 ET | 600 | 1.59 |
03:36 ET | 200 | 1.59 |
03:38 ET | 100 | 1.59 |
03:39 ET | 2800 | 1.59 |
03:41 ET | 1700 | 1.59 |
03:43 ET | 1200 | 1.595 |
03:45 ET | 300 | 1.59 |
03:48 ET | 30157 | 1.605 |
03:50 ET | 300 | 1.61 |
03:52 ET | 1966 | 1.6 |
03:54 ET | 3188 | 1.61 |
03:56 ET | 14271 | 1.61 |
03:57 ET | 9601 | 1.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 109.0M | -84.2x | --- |
Spero Therapeutics Inc | 77.6M | 3.6x | --- |
2Seventy Bio Inc | 235.5M | -1.0x | --- |
Rigel Pharmaceuticals Inc | 187.7M | -7.3x | --- |
Fortress Biotech Inc | 33.1M | -0.2x | --- |
Seres Therapeutics Inc | 137.3M | -1.1x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $109.0M |
---|---|
Revenue (TTM) | $101.2M |
Shares Outstanding | 67.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-0.02 |
Book Value | $-0.70 |
P/E Ratio | -84.2x |
Price/Sales (TTM) | 1.1 |
Price/Cash Flow (TTM) | 67.9x |
Operating Margin | -6.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.